Do supervised injecting facilities attract higher-risk injection drug users?

[1]  R. Hogg,et al.  Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users. , 2006, Health & place.

[2]  J. Montaner,et al.  Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users , 2004, Harm reduction journal.

[3]  J. Montaner,et al.  Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users , 2004, Canadian Medical Association Journal.

[4]  J. Frankish,et al.  The Future Face of Coinfection: Prevalence and Incidence of HIV and Hepatitis C Virus Coinfection Among Young Injection Drug Users , 2004, Journal of acquired immune deficiency syndromes.

[5]  J. Montaner,et al.  Rationale for evaluating North America's first medically supervised safer-injecting facility. , 2004, The Lancet. Infectious diseases.

[6]  J. Strang,et al.  Supervised fixing rooms, supervised injectable maintenance clinics—understanding the difference , 2004, BMJ : British Medical Journal.

[7]  N. Wright,et al.  Supervised injecting centres , 2004 .

[8]  M. Schechter,et al.  Responding to an Explosive HIV Epidemic Driven by Frequent Cocaine Injection: Is There a Role for Safe Injecting Facilities? , 2003 .

[9]  J. Kimber,et al.  Drug consumption facilities: an update since 2000. , 2003, Drug and alcohol review.

[10]  S. Galea,et al.  Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. , 2003, Addiction.

[11]  M. Schechter,et al.  Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic , 2003, AIDS.

[12]  R. Hogg,et al.  The Potential Public Health and Community Impacts of Safer Injecting Facilities: Evidence From a Cohort of Injection Drug Users , 2003, Journal of acquired immune deficiency syndromes.

[13]  R. Hogg,et al.  Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. , 2002, AIDS.

[14]  M. Schechter,et al.  Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[15]  M. Schechter,et al.  Impact of HIV Infection on Mortality in a Cohort of Injection Drug Users , 2001, Journal of acquired immune deficiency syndromes.

[16]  T. Kerr,et al.  Safe injection facilities in Canada: is it time? , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[17]  J. Montaner,et al.  Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[18]  D. Vlahov,et al.  Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective. , 2001, Archives of internal medicine.

[19]  E. Drucker,et al.  Fatal Overdose Trends in Major us Cities: 1990–1997 , 2001 .

[20]  D. McDonald,et al.  Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia , 2000 .

[21]  G. Yamey.  UN condemns Australian plans for “safe injecting rooms” , 2000, BMJ : British Medical Journal.

[22]  Heather Miller,et al.  Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial , 1999, The Lancet.

[23]  Wouter Jong,et al.  The professional acceptance of drug use: a closer look at drug consumption rooms in the Netherlands, Germany and Switzerland , 1999 .

[24]  B. Yip,et al.  Barriers to use of free antiretroviral therapy in injection drug users. , 1998, JAMA.

[25]  Julio S. G. Montaner,et al.  Needle exchange is not enough: lessons from the Vancouver injecting drug use study , 1997, AIDS.

[26]  D. D. Des Jarlais,et al.  Maintaining low HIV seroprevalence in populations of injecting drug users. , 1995, JAMA.

[27]  D. D. Des Jarlais,et al.  Targeted HIV-prevention programs. , 1994, The New England journal of medicine.

[28]  D. Hedrich.  European report on drug consumption rooms. , 2004 .